Autoimmune Disease Diagnosis Market by Product (Consumables, Assay Kits, Instruments), Test Type (Inflammatory Markers, Routine Laboratory Tests), Disease (RA, SLE, Thyroiditis, Scleroderma), End User (Hospitals, Clinical Labs) & Region – Global Forecast to 2025
Market Growth Outlook Summary
The global autoimmune disease diagnosis market growth forecasted to transform from USD 4.1 billion in 2020 to USD 6.3 billion by 2025, driven by a CAGR of 8.9%. This industry is experiencing significant growth due to the high incidence of autoimmune diseases, increasing awareness about autoimmune diseases, and the growth in research on autoimmune diseases.
Consumables & assay kits segment to dominate the autoimmune disease diagnosis market in 2019
Based on the product, the autoimmune disease diagnosis industry is segmented into consumables & assay kits and instruments. The consumables & assay kits segment is expected to grow at the highest growth rate during the forecast period. This is attributed primarily to the rising incidence of autoimmune disease and the increasing number of product launches/approvals.
Routine laboratory tests segment to dominate the autoimmune disease diagnosis market in 2019
Based on the test type, the autoimmune disease diagnosis industry is segmented into routine laboratory tests, inflammatory markers, autoantibodies & immunologic tests, and other tests. The routine laboratory tests segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed to the increasing prevalence of autoimmune diseases coupled with advanced healthcare infrastructure in the region.
Europe was the largest regional market for autoimmune disease diagnosis in 2019
The autoimmune disease diagnosis market has been analyzed for North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, Europe held the largest share of the market, followed by Asia Pacific. The rising incidences of chronic diseases, the increasing geriatric population in this region are the major factors driving the growth of the autoimmune disease diagnosis industry in Europe.
The prominent players operating in autoimmune disease diagnosis market include Thermo Fisher Scientific (US), Siemens (Germany), Abbott (US), Danaher (US), Bio-Rad Laboratories (US), Grifols (Spain), Trinity Biotech (Ireland), Werfen (Spain), HYCOR Biomedical (US), EUROIMMUN AG (Germany), Oncimmune (UK), HTG Molecular Diagnostics (US), Seramun Diagnostica GmbH (Germany), Exagen Inc. (US), Cambridge Life Sciences Limited (UK), A. Menarini Diagnostics s.r.l (Italy), ORGENTEC Diagnostika (Germany), KRONUS (US), and AESKU GROUP GMBH & CO. KG (Germany).
Siemens AG (Germany) is one of the leading players in the autoimmune disease diagnosis market in 2019. The company offers a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the market.
Scope of the Autoimmune Disease Diagnosis Industry
|
Report Metric |
Details |
|
Market Revenue Size in 2020 |
$4.1 billion |
|
Projected Revenue Size by 2025 |
$6.3 billion |
|
Industry Growth Rate |
Poised to Grow at a CAGR of 8.9% |
|
Market Driver |
High incidence and prevalence of autoimmune diseases |
|
Market Opportunity |
Use of biosensors for autoimmune disease diagnosis |
This research report categorizes the autoimmune disease diagnosis market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Consumables & Assay Kits
- Instruments
By Test Type
- Routine Laboratory Tests
- Inflammatory Markers
- Autoantibodies & Immunologic Test
- Other Tests
By Disease
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjögren’s Syndrome
- Thyroiditis
- Scleroderma
- Other Diseases
By End User
- Clinical Laboratories
- Hospitals
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- RoE
-
Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments of Autoimmune Disease Diagnosis Industry:
- In 2019, Cambridge Life Sciences Limited launched ZEUS IFA Test Systems in the US.
- In 2019, PerkinElmer, Inc. received approval from the US FDA EUROIMMUN Anti-Tissue Transglutaminase ELISA to help clinicians confirm or exclude a celiac disease diagnosis.
- In 2019, Exagen Inc. extended its agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management.
Key Questions Addressed by the Report:
- What are the various autoimmune disease diagnosis and their respective market shares in the overall market?
- Where will these developments shape the industry in the mid-to-long term?
- What are the recent trends affecting the autoimmune disease diagnosis market?
- Who are the key players in the market, and how intense is the competition?
- What are the new trends and advancements in the autoimmune disease diagnosis market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 17)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 20)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
3 EXECUTIVE SUMMARY (Page No. - 26)
4 PREMIUM INSIGHTS (Page No. - 30)
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE AUTOIMMUNE DISEASE DIAGNOSIS MARKET
4.2 ASIA PACIFIC MARKET: BY DISEASE
4.3 AUTOIMMUNE DISEASE DIAGNOSIS MARKET: GEOGRAPHIC SNAPSHOT
5 MARKET OVERVIEW (Page No. - 33)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 High incidence and prevalence of autoimmune diseases
5.2.1.2 Increasing awareness about autoimmune diseases
5.2.1.3 Growth in the number of research activities on autoimmune diseases
5.2.2 RESTRAINTS
5.2.2.1 High capital requirements
5.2.3 OPPORTUNITIES
5.2.3.1 Use of biosensors for autoimmune disease diagnosis
5.2.4 TRENDS
5.2.4.1 Growth in the number of reagent rental agreements
6 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT (Page No. - 38)
6.1 INTRODUCTION
6.2 CONSUMABLES & ASSAY KITS
6.2.1 NEED FOR THE RAPID DETECTION OF AUTOIMMUNE DISEASES TO DRIVE THE DEMAND FOR CONSUMABLES AND ASSAY KITS
6.3 INSTRUMENTS
6.3.1 INSTRUMENTS SEGMENT TO RECORD SIGNIFICANT GROWTH DURING THE FORECAST PERIOD
7 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE (Page No. - 42)
7.1 INTRODUCTION
7.2 ROUTINE LABORATORY TESTS
7.2.1 RISING NUMBER OF ROUTINE HEALTH CHECK-UPS TO SUPPORT MARKET GROWTH
7.3 INFLAMMATORY MARKERS
7.3.1 ABILITY OF INFLAMMATORY MARKERS TO DETECT ABNORMALITIES EFFICIENTLY TO DRIVE THEIR DEMAND
7.4 AUTOANTIBODIES AND IMMUNOLOGIC TESTS
7.4.1 ADOPTION OF NOVEL IMMUNOLOGY TESTS TO DRIVE MARKET GROWTH
7.5 OTHER TESTS
8 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE (Page No. - 47)
8.1 INTRODUCTION
8.2 RHEUMATOID ARTHRITIS
8.2.1 INCREASING INCIDENCE OF RHEUMATOID ARTHRITIS TO SUPPORT MARKET GROWTH
8.3 SYSTEMIC LUPUS ERYTHEMATOSUS
8.3.1 RISING PREVALENCE OF LUPUS TO SUPPORT MARKET GROWTH
8.4 SJÖGREN’S SYNDROME
8.4.1 RISING AWARENESS REGARDING SJÖGREN’S SYNDROME TO SUPPORT MARKET GROWTH
8.5 THYROIDITIS
8.5.1 RISING PREVALENCE OF THYROID DISORDERS TO DRIVE MARKET GROWTH
8.6 SCLERODERMA
8.6.1 INCREASING INCIDENCE OF SKIN DISORDERS TO DRIVE MARKET GROWTH
8.7 OTHER DISEASES
9 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER (Page No. - 54)
9.1 INTRODUCTION
9.2 CLINICAL LABORATORIES
9.2.1 INCREASING INCIDENCE OF AUTOIMMUNE DISEASES TO INCREASE TESTING VOLUME IN CLINICAL LABORATORIES
9.3 HOSPITALS
9.3.1 INCREASING GOVERNMENT INITIATIVES TO PROVIDE QUALITY TREATMENT FOR AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
9.4 OTHER END USERS
10 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY REGION (Page No. - 58)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Rising expenditure on autoimmune disease R&D to drive market growth in the US
10.2.2 CANADA
10.2.2.1 Rising prevalence of autoimmune diseases to support market growth
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Rising healthcare expenditure to drive market growth in Germany
10.3.2 UK
10.3.2.1 Rising prevalence of autoimmune diseases to drive market growth in the UK
10.3.3 FRANCE
10.3.3.1 High prevalence of multiple sclerosis to drive market growth in France
10.3.4 ITALY
10.3.4.1 Increasing life science R&D expenditure to support market growth in Italy
10.3.5 SPAIN
10.3.5.1 Research activities conducted in the country to drive market growth in Spain
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Outbreak of COVID-19 to hamper market growth during the forecast period
10.4.2 INDIA
10.4.2.1 Development of antibody tests to support market growth in India
10.4.3 JAPAN
10.4.3.1 Rising healthcare expenditure to support market growth in Japan
10.4.4 AUSTRALIA
10.4.4.1 Rising prevalence of autoimmune diseases to drive market growth in Australia
10.4.5 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH IN THE MIDDLE EAST AND AFRICA
10.6 LATIN AMERICA
10.6.1 HIGH PREVALENCE OF RHEUMATOID ARTHRITIS TO SUPPORT MARKET GROWTH IN LATIN AMERICA
11 COMPETITIVE LANDSCAPE (Page No. - 94)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2018
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES (2017-2020)
11.3.2 PRODUCT APPROVALS (2017-2020)
11.3.3 PARTNERSHIPS
11.3.4 ACQUISITIONS (2017-2020)
11.3.5 COLLABORATIONS (2017-2020)
11.4 COMPETITIVE LEADERSHIP MAPPING (2018)
11.4.1 VISIONARY LEADERS
11.4.2 INNOVATORS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES
12 COMPANY PROFILES (Page No. - 101)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 SIEMENS
12.3 ABBOTT
12.4 DANAHER
12.5 BIO-RAD LABORATORIES
12.6 GRIFOLS
12.7 TRINITY BIOTECH
12.8 WERFEN
12.9 HYCOR BIOMEDICAL
12.10 EUROIMMUN
12.11 ONCIMMUNE
12.12 HTG MOLECULAR DIAGNOSTICS, INC.
12.13 SERAMUN DIAGNOSTICA GMBH
12.14 EXAGEN INC.
12.15 CAMBRIDGE LIFE SCIENCES LIMITED
12.16 A. MENARINI DIAGNOSTICS S.R.L
12.17 ORGENTEC DIAGNOSTIKA
12.18 KRONUS
12.19 ERBA GROUP
12.20 AESKU.GROUP GMBH & CO. KG
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 143)
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
LIST OF TABLES (96 Tables)
TABLE 1 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 2 AUTOIMMUNE DISEASE DIAGNOSIS CONSUMABLES & ASSAY KITS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 3 AUTOIMMUNE DISEASE DIAGNOSIS INSTRUMENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 4 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 5 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR ROUTINE LABORATORY TESTS, BY REGION, 2018–2025 (USD MILLION)
TABLE 6 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR INFLAMMATORY MARKERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 7 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR AUTOANTIBODIES AND IMMUNOLOGIC TESTS, BY REGION, 2018–2025 (USD MILLION)
TABLE 8 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR OTHER TESTS, BY REGION, 2018–2025 (USD MILLION)
TABLE 9 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 10 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2018–2025 (USD MILLION)
TABLE 11 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018–2025 (USD MILLION)
TABLE 12 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR SJÖGREN’S SYNDROME, BY REGION, 2018–2025 (USD MILLION)
TABLE 13 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR THYROIDITIS, BY REGION, 2018–2025 (USD MILLION)
TABLE 14 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR SCLERODERMA, BY REGION, 2018–2025 (USD MILLION)
TABLE 15 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR OTHER DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 16 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER,2018–2025 (USD MILLION)
TABLE 17 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 18 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR HOSPITALS, BY REGION, 2018–2025 (USD MILLION)
TABLE 19 AUTOIMMUNE DISEASE DIAGNOSIS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 20 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 21 NORTH AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 22 NORTH AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 23 NORTH AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 24 NORTH AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 25 NORTH AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 26 EXPENDITURE ON AUTOIMMUNE DISEASE R&D BY THE NATIONAL INSTITUTES OF HEALTH, 2016–2019
TABLE 27 US: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 28 US: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE,2018–2025 (USD MILLION)
TABLE 29 US: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 30 US: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 31 CANADA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 32 CANADA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 33 CANADA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 34 CANADA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 35 EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 36 EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT,2018–2025 (USD MILLION)
TABLE 37 EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 38 EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 39 EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER,2018–2025 (USD MILLION)
TABLE 40 GERMANY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 41 GERMANY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 42 GERMANY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 43 GERMANY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 44 UK: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 45 UK: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 46 UK: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 47 UK: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 48 FRANCE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 49 FRANCE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 50 FRANCE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 51 FRANCE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 52 ITALY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 53 ITALY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 54 ITALY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 55 ITALY: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 56 SPAIN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 57 SPAIN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 58 SPAIN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 59 SPAIN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 60 REST OF EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 61 REST OF EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 62 REST OF EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 63 REST OF EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 64 ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 65 ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 66 ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 67 ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE,2018–2025 (USD MILLION)
TABLE 68 ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 69 CHINA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 70 CHINA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 71 CHINA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 72 CHINA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 73 INDIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 74 INDIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 75 INDIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 76 INDIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 77 JAPAN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 78 JAPAN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 79 JAPAN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 80 JAPAN: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 81 AUSTRALIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 82 AUSTRALIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 83 AUSTRALIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 84 AUSTRALIA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 85 REST OF ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 86 REST OF ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 87 REST OF ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 88 REST OF ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 90 MIDDLE EAST & AFRICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 92 MIDDLE EAST & AFRICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 93 LATIN AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 94 LATIN AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 95 LATIN AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2018–2025 (USD MILLION)
TABLE 96 LATIN AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2018–2025 (USD MILLION)
LIST OF FIGURES (34 Figures)
FIGURE 1 AUTOIMMUNE DISEASE DIAGNOSIS MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 5 MARKET SIZE ESTIMATION FROM THE PARENT MARKET
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 ASSUMPTIONS FOR THE STUDY
FIGURE 8 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 9 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY TEST TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 10 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY DISEASE, 2020 VS. 2025 (USD MILLION)
FIGURE 11 AUTOIMMUNE DISEASE DIAGNOSIS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
FIGURE 12 GEOGRAPHIC SNAPSHOT OF THE GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET
FIGURE 13 HIGH INCIDENCE & LARGE ECONOMIC BURDEN OF AUTOIMMUNE DISEASES TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
FIGURE 14 RHEUMATOID ARTHRITIS SEGMENT DOMINATED THE APAC MARKET IN 2019
FIGURE 15 JAPAN TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 16 AUTOIMMUNE DISEASE DIAGNOSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & TRENDS
FIGURE 17 NORTH AMERICA: AUTOIMMUNE DISEASE DIAGNOSIS MARKET SNAPSHOT
FIGURE 18 EUROPE: AUTOIMMUNE DISEASE DIAGNOSIS MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: AUTOIMMUNE DISEASE DIAGNOSIS MARKET SNAPSHOT
FIGURE 20 PRODUCT LAUNCHES–THE MOST ADOPTED GROWTH STRATEGY FROM 2017 TO 2020
FIGURE 21 SHARES OF TOP COMPANIES IN THE GLOBAL AUTOIMMUNE DISEASE DIAGNOSIS MARKET (2018)
FIGURE 22 AUTOIMMUNE DISEASE DIAGNOSIS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2018
FIGURE 23 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 24 SIEMENS: COMPANY SNAPSHOT
FIGURE 25 ABBOTT: COMPANY SNAPSHOT
FIGURE 26 DANAHER: COMPANY SNAPSHOT
FIGURE 27 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
FIGURE 28 GRIFOLS: COMPANY SNAPSHOT
FIGURE 29 TRINITY BIOTECH: COMPANY SNAPSHOT
FIGURE 30 WERFEN: COMPANY SNAPSHOT
FIGURE 31 PERKINELMER, INC.: COMPANY SNAPSHOT
FIGURE 32 ONCIMMUNE: COMPANY SNAPSHOT
FIGURE 33 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT
FIGURE 34 EXAGEN INC.: COMPANY SNAPSHOT
The study involved four major activities in estimating the current size of the autoimmune disease diagnosis market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Then, both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
The secondary sources referred to for research study on the autoimmune disease diagnosis market include publications from government sources such as white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations were referred to identify and collect information for this study.
Primary Research
The autoimmune disease diagnosis market comprises several stakeholders, such as autoimmune disease diagnosis manufacturers and distributors. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the autoimmune disease diagnosis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research.
- The industry's supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall autoimmune disease diagnosis market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the autoimmune disease diagnosis industry.
Report Objectives
- To define, describe, segment, and forecast the autoimmune disease diagnosis market by product, test type, disease, end user, and region
- To forecast the size of the market with respect to the main regional segments—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key players and comprehensively analyze their market shares and core competencies2 in terms of market developments and growth strategies
- To track and analyze competitive developments such as collaborations, regulatory approvals, partnerships, acquisitions, and product launches in the autoimmune disease diagnosis market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company's specific needs. The following customization options are available for the autoimmune disease diagnosis market report:
Product Analysis:
- Product matrix, which gives a detailed comparison of the product portfolios of each company
Company Information:
- Detailed analysis and profiling of additional market players (Up to 5)
Generating Response ...
Growth opportunities and latent adjacency in Autoimmune Disease Diagnosis Market